Accugenomics

AccuGenomics is a life science tools developer with a disruptive technology to improve the accuracy of sequencing tests (NGS) in precision medicine. Improve diagnostic accuracy and monitor any treatment response (MRD) by addressing inaccurate NGS tests. AccuGenomics has commercialized SNAQ-SEQ, a proprietary and highly differentiated internal Quality Control (QC) standard technology used in next generation sequencing (NGS) diagnostics. Internal standard mixtures are easily incorporated into existing NGS platforms and improve the sensitivity and specificity of the result for early detection and monitoring (MRD) tests. Biopsies from blood represent a powerful and sensitive tool for clinicians that are rapidly being adopted, but to date, inaccurate results at lower detection limits are impacting clinical utility. AccuGenomics disruptive technology is spiked into every patient sample and offers unparalleled confidence in the result - especially at the assay limit of detection. SNAQ-SEQ technology provides a scalable industry wide solution for standardized sequencing methods with enhanced sensitivity and specificity for low level targets like ctDNA, to eliminate false positive and false negatives results that lead to unnecessary medical procedures and poorer patient outcomes. AccuGenomics has multiple existing products (Myeloid, CRC/NSCLC, ctDNA MRD, TP53, Breast Cancer) and also provides custom mixtures of internal standards. We also have products for pathogen testing (SARS-CoV-2, Influenza etc) and provide internal standards for bio manufacturing QC lot release / adventitious agents / AAV and more.